Advertisement

Advertisement

HK:2105 Stock Latest News

Laekna Signals Sharp Interim Turnaround on Licensing Revenue

Company AnnouncementsLaekna Signals Sharp Interim Turnaround on Licensing Revenue

Laekna’s Breast Cancer Drug LAE002 Wins NDA Acceptance in China

PremiumCompany Announcements

Laekna’s Breast Cancer Drug LAE002 Wins NDA Acceptance in China

6d ago

Laekna Schedules Board Meeting to Approve 2026 Interim Results

PremiumCompany Announcements

Laekna Schedules Board Meeting to Approve 2026 Interim Results

11d ago

Laekna Unveils HK$56 Million Insider-Backed Share Buyback Plan

PremiumCompany Announcements

Laekna Unveils HK$56 Million Insider-Backed Share Buyback Plan

2M ago

Laekna Streamlines Company Secretary and Governance Roles After HKEX Qualification Approval

PremiumCompany Announcements

Laekna Streamlines Company Secretary and Governance Roles After HKEX Qualification Approval

2M ago

Laekna Grants Vasque Bio Global Rights to LAE118 Outside Greater China

PremiumCompany AnnouncementsLaekna Grants Vasque Bio Global Rights to LAE118 Outside Greater China

2M ago

Laekna Shareholders Approve All Resolutions at 2026 AGM

Company Announcements

Laekna Shareholders Approve All Resolutions at 2026 AGM

2M ago

Laekna Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate

Company Announcements

Laekna Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate

3M ago

Laekna grants 15.3 million RSUs under 2024 share award scheme

PremiumCompany Announcements

Laekna grants 15.3 million RSUs under 2024 share award scheme

3M ago

Laekna’s Breast Cancer Drug LAE002 Hits Phase III PFS Goal, NDA in China Planned

PremiumCompany Announcements

Laekna’s Breast Cancer Drug LAE002 Hits Phase III PFS Goal, NDA in China Planned

4M ago

Laekna Advances Obesity Candidate LAE102 With Positive Phase I Data

PremiumCompany Announcements

Laekna Advances Obesity Candidate LAE102 With Positive Phase I Data

5M ago

Laekna Announces Positive Phase I Results for Obesity-Targeted Antibody LAE102

PremiumCompany Announcements

Laekna Announces Positive Phase I Results for Obesity-Targeted Antibody LAE102

5M ago

Laekna Sets March 2026 Board Meeting to Approve 2025 Annual Results

PremiumCompany AnnouncementsLaekna Sets March 2026 Board Meeting to Approve 2025 Annual Results

5M ago

Laekna Wins FDA Acceptance of IND for New PI3Kα Inhibitor LAE118

Company Announcements

Laekna Wins FDA Acceptance of IND for New PI3Kα Inhibitor LAE118

7M ago

Laekna Doses First Subject in Phase I Trial of Metabolic Drug Candidate LAE103

Company Announcements

Laekna Doses First Subject in Phase I Trial of Metabolic Drug Candidate LAE103

8M ago

Laekna Doses First Patient in Phase I Multiple-Dose Expansion Study of Obesity Drug LAE102

PremiumCompany Announcements

Laekna Doses First Patient in Phase I Multiple-Dose Expansion Study of Obesity Drug LAE102

8M ago

Laekna Completes Enrollment for Phase III Breast Cancer Trial

PremiumCompany Announcements

Laekna Completes Enrollment for Phase III Breast Cancer Trial

8M ago

Laekna, Inc. Updates Nomination and Governance Committee

PremiumCompany Announcements

Laekna, Inc. Updates Nomination and Governance Committee

8M ago

Laekna, Inc. Announces Board of Directors and Committee Roles

PremiumCompany Announcements

Laekna, Inc. Announces Board of Directors and Committee Roles

8M ago

Laekna, Inc. Updates Governance Committee Terms

PremiumCompany AnnouncementsLaekna, Inc. Updates Governance Committee Terms

8M ago

Laekna, Inc. Partners with Qilu Pharma for Exclusive Licensing of LAE002 in China

Company Announcements

Laekna, Inc. Partners with Qilu Pharma for Exclusive Licensing of LAE002 in China

9M ago

Laekna, Inc. Advances Breast Cancer Treatment with Promising Clinical Study

Company Announcements

Laekna, Inc. Advances Breast Cancer Treatment with Promising Clinical Study

10M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >